NetraMark Holdings Inc. reports developments tied to artificial intelligence for clinical trial optimization and precision medicine in the pharmaceutical industry. Its recurring updates center on the NetraAI platform, which is designed to analyze complex clinical datasets, identify model-derived patient subgroups, and support patient stratification, enrichment strategies, and trial-design decisions.
Company news commonly covers pharmaceutical and research collaborations, contracts to analyze clinical trial data, peer-reviewed work, conference presentations, and clinical leadership additions. Reported therapeutic areas include central nervous system disorders, depression, Alzheimer’s disease, oncology, and regulated botanical wellness, with emphasis on explainable analytics, biomarker-guided insights, and responder or placebo-sensitive patient populations.
NetraMark (AINMF) announced that founder Dr. Joseph Geraci will participate in H.C. Wainwright’s virtual AI drug discovery conference on October 8–9, 2026.
Geraci, Chief Scientific and Technical Officer, will join the panel “Design Got Cheap - Where Is the Defensible Moat?”, scheduled for 4:00–5:00 p.m. Eastern Time. The discussion will explore competitive differentiation in AI-based drug discovery and development. Fellow panelists are BigHat Biosciences CEO and co-founder Peyton Greenside and MindWalk AI CEO Jennifer Bath, with H.C. Wainwright Managing Director Swayampakula Ramakanth moderating.
NetraMark (AINMF) reported that a peer-reviewed study in MDPI’s AI journal found its NetraAI platform improved the predictive performance of eight industry-standard AI and machine-learning models across three retrospective clinical datasets in schizophrenia, major depressive disorder and pancreatic cancer.
The study compared those models on original trial data versus on compact biological and clinical variable sets discovered by NetraAI; performance on the original data was generally weak to modest, but every model improved on every dataset when using NetraAI-derived variables. A pretrained foundation model that initially achieved near-chance 0.53–0.59 AUC on the original data reached substantially higher AUC, including a near-perfect result in a pancreatic cancer subgroup, when given NetraAI’s variables. In one pancreatic cancer analysis, NetraAI reduced about 25,000 genomic variables to a three-variable signature linked to regimen-associated response, which other models then used to reach near-perfect accuracy in that called subgroup, though the result remains exploratory and requires external validation.
NetraMark (AINMF) has appointed veteran global finance executive Kevin Felix as Strategic Advisor to support its commercialization and capital markets strategy.
Felix has more than 25 years of senior leadership experience in capital markets, asset management, corporate strategy and securities law. He most recently served as President of the Investment Office of Global Atlantic Financial Group, overseeing business management and operations for a $175 billion investment portfolio. His prior roles at Scotiabank included President and CEO of Scotia Capital (USA) and Global Head of Fixed Income, Currencies and Commodities. As Strategic Advisor, he will counsel NetraMark on institutional investor and banking relationships, strategic transactions, corporate development and longer-term capital markets strategy in Canada and the United States.
NetraMark (OTCQB: AINMF) announced the appointment of veteran pharmaceutical executive Dr. Keith M. Fournier to its Board of Directors. Dr. Fournier brings over 20 years of global drug development, regulatory strategy and portfolio leadership experience from roles at AbbVie, Merck KGaA’s EMD Serono, AstraZeneca’s MedImmune and Abivax.
He has led regulatory and cross-functional strategies across major programs, including VENCLEXTA and HUMIRA, and currently serves as Senior Vice President, Head of Regulatory Affairs at Abivax. According to NetraMark, his expertise in regulatory decision-making and clinical development is expected to support the Company’s AI-driven clinical trial analytics strategy and its engagement with pharmaceutical and biotechnology partners.
NetraMark (OTCQB: AINMF) will participate in the H.C. Wainwright 28th Annual Global Investment Conference. CEO George Achilleos will deliver a virtual corporate presentation available on-demand starting September 11, 2026 at 7:00 a.m. ET, covering commercial, clinical, regulatory progress and the NetraAI platform.
NetraMark senior management will also hold in-person, one-on-one investor meetings at the Lotte New York Palace Hotel in New York City on September 14–15, 2026. Interested parties can access the online presentation via the provided presentation link, and learn more at www.netramark.com.
NetraMark (OTCQB: AINMF)/b) reported a sharp expansion in its commercial activity for fiscal 2026, driven by its NetraAI clinical-trial analytics platform. The company entered fiscal 2026 with approximately C$322,000 in booked contract value and has added about C$3.415 million in new contracts, lifting total booked contract value available for execution in 2026 and future periods to roughly C$3.737 million. New contracts are up about 645% versus the prior annual high of C$458,000. For the first nine months of fiscal 2026, NetraMark recognized revenue of C$559,564, up about 45% from C$386,085 a year earlier, with about C$3.18 million of booked value still unrecognized. Operational highlights include a new late-stage biopharmaceutical engagement, the first commercial project through a CRO partner, appointment of a fractional Chief Medical Officer, growing CRO bid activity, and continued scientific and regulatory-focused research across psychiatry, neurodegeneration and oncology.
NetraMark (OTCQB: AINMF) has engaged AM Public Relations, a healthcare-focused communications agency, to support its strategic communications and market awareness. The collaboration is intended to help communicate NetraMark’s clinical development initiatives, its proprietary NetraAI platform, and broader scientific and commercial progress.
According to NetraMark, AM PR will assist in reaching key audiences such as investors, potential partners, industry stakeholders, and the healthcare community by translating complex clinical trial and AI technology concepts into clear narratives that highlight NetraAI’s role in generating insights from clinical trial data and in explainable AI for drug development.
NetraMark (OTCQB: AINMF) signed a new contract to analyze a phase 2 neurodegeneration clinical trial dataset through its contract research organization (CRO) partner, marking its first engagement routed via a CRO.
The project uses the proprietary NetraAI platform to identify explainable Model-Derived Subgroups and treatment-response patterns in central nervous system (CNS) disorders, aiming to support patient stratification, trial design, and future drug-development decisions.
NetraMark (OTCQB: AINMF) signed a new NetraAI clinical trial analysis agreement with a biopharmaceutical company developing a late-stage central nervous system therapy. This is NetraMark’s ninth commercial contract since October 2025, highlighting growing use of its AI platform in late-stage clinical development.
NetraAI will analyze patient-level data from a completed mid-to-late-stage trial, generating insights on dose response, efficacy, safety, tolerability, cognition, functional outcomes, discontinuation patterns, and patient stratification to support the client’s late-stage program decisions.
NetraMark (OTCQB: AINMF) will deliver a corporate presentation at the virtual Sidoti Small Cap Conference on June 18, 2026, at 9:15 a.m. ET. Senior management will discuss commercial, clinical, and regulatory progress for NetraAI, its proprietary AI platform for pharmaceutical clinical trials.
NetraMark will also hold one-on-one virtual meetings on June 17–18, 2026.